Navigation Links
Tosedostat OPAL Study Final Results Selected for Oral Presentation at the 2011 American Society of Hematology (ASH) Annual Meeting
Date:12/6/2011

SEATTLE, Dec. 7, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that final results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia ("AML") was selected as on oral presentation at the 2011 American Society of Hematology ("ASH") Annual Meeting, which will be held on December 10-13, 2011, in San Diego, California.

Jorge Cortes, M.D., of The University of Texas MD Anderson Cancer Center, an investigator on the tosedostat study, is scheduled to present the data on Monday, December 12, 2011, during the "Acute Myeloid Leukemia - Therapy, excluding Transplantation: Clinical Studies" session that will be held from 4:30 p.m. to 6:00 p.m. Pacific time. The presentation, abstract #767, is titled, "Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia."

Additionally, results from CTI's PIX203 phase II study, in which pixantrone was substituted for doxorubicin in the CPOP-R regimen compared to the standard CHOP-R regimen in front-line aggressive non-Hodgkin's lymphoma was selected for a poster presentation.  The poster is scheduled to be presented in the "Lymphoma – Chemotherapy, excluding Pre-Clinical Models: Poster I" session on Saturday, December 10, 2011 that will be held from 5:30 to 7:30 p.m. Pacific time. The poster, abstract #1605, is titled "CPOP-R Versus CHOP-R as First-Line Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-Label, Multicenter Study."  

The study abstracts are available at www.hematology.org.

Investor and Analyst Meeting

Separately, CTI will host an investor and analyst meeting to present and discuss unmet medical needs in aggressive non-Hodgkin's lymphoma ("NHL"), AML and myelodysplastic s
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmathene Announces Publication of Phase I Study Results for Anthrax Anti-toxin Valortim®
2. Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
3. New Study Shows AFECTAIR® Significantly Improved Delivery of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions
4. First Patient Enrolled in Therakos Phase Two Study for Treatment of Graft-versus-Host Disease
5. New Gene Study of ADHD Points to Defects in Brain Signaling Pathways
6. RECITAL Study Presents Excellent Outcomes and Rapid Patient Recovery With Revolutionary Femoral Access Procedure
7. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
8. Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinsons Disease
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Combination Study of MM-121 and Multiple Anticancer Therapies in Patients with Advanced Solid Tumors
10. BioMarin Initiates Phase 2 Study for GALNS in Patients Under Five Years of Age With MPS IVA
11. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... , September 11, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has announced the ... Identification (RFID) Market in Healthcare (Tags, ... Industry Analysis, Size, Share, Growth, Trends ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:9/11/2014)... , Sept. 11, 2014 Array BioPharma Inc. ... focused on the discovery, development and commercialization of ... cancer, today announced the appointment of Victor ... Sandor will be responsible for leading clinical, medical ... portfolio, including binimetinib, a MEK inhibitor in Phase ...
Breaking Medicine Technology:Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 2Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 4
(Date:9/14/2014)... September 14, 2014 Proper oral care ... from Butte, Mont., found a way to teach children ... patent-pending B LITE toothbrush encourages an effective brushing habit ... full two minutes without overbrushing, eliminating guesswork and promoting ... easy to use, suitable for all children, and producible ...
(Date:9/14/2014)... Top10BestSEOHosting.com always offers truly reliable ... host suppliers carefully, the site has announced that ... the Best WordPress Hosting suppliers in the current ... top web hosting provider, and the company’s reputation ... hosting provider known for its flexible hosting packages, ...
(Date:9/14/2014)... 2014 UWDress.com, is an internationally well-known ... recently announced its new range of cocktail dresses ... more benefits to worldwide ladies, the company is also ... wedding outfits, blue evening gowns, black formal gowns and ... percent off. , The company’s senior spokesman says, ...
(Date:9/13/2014)... 2014 East Vancouver chiropractor from ... chiropractic clinic, has recently published a blog busting ... blog on the topic, Dr Shervin Ranjbar has ... that people have regarding this branch of medicine. ... of a chiropractor and that of a physiotherapist, ...
(Date:9/13/2014)... (HealthDay News) -- Researchers say they,ve tracked specific activity ... hasn,t been clear whether imagination and memory were distinct ... Provo, Utah, decided to explore the issue. "I ... future and imagining myself in the future, and I ... co-author Stefania Ashby said in a university news release. ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: The Best Linux Web Hosting Suppliers Now Unveiled 2Health News:UWDress.com: Elegant Cocktail Dresses Under $100 Now Offered 2Health News:East Vancouver Chiropractor Releases Blog to Bust Myths about Chiropractic Medicine 2Health News:Scientists Watch Imagination at Work in the Brain 2
... Tender Offer Connected with Previously Announced Plans to Separate Medical ... Technology and Funeral Services Businesses, ... ) (the "Company") announced today that it has,commenced a cash ... percent Senior Notes due 2009 (CUSIP No. 431573AD6), of which ...
... 29 Orchid Cellmark Inc.,(Nasdaq: ORCH ), a ... its fourth quarter and full year 2007 financial,results on ... and is,hosting a conference call and webcast to discuss ... Management will discuss financial results for the,fourth quarter and ...
... With the State of,Minnesota facing a $935 million ... to ensure that the health and independence of,the ... "On the one hand, legislators are discussing meaningful ... chronic conditions, and on the,other, we expect the ...
... The Board of,Directors of Schering-Plough Corporation (NYSE: ... for Ian McInnes, Ph.D., to senior vice,president and ... vice,president, Global Supply Chain. The change reflects the ... that now includes operations from,Organon BioSciences N.V., acquired ...
... the disease , , FRIDAY, Feb. 29 (HealthDay News) -- While ... also play a major role in the development of the ... on more than 40,000 twins born in 1958 or earlier, ... risk for chronic bronchitis and that 14 percent of the ...
... Feb. 29 The American people,through the ... and,a consortium of four partners, will assist ... implement HIV/AIDS prevention, malaria and child,survival programs. ... project,will involve district stakeholders, the private sector ...
Cached Medicine News:Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 2Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 3Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 4Health News:Hillenbrand Industries, Inc. Announces 'Any and All' Cash Tender Offer for Its 4.50 percent Senior Notes Due 2009 5Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:USAID Implements Behavior Change and Social Marketing Program in Rwanda 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: